Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab
Andrew Staron(Boston University), Vaishali Sanchorawala(Boston Medical Center), Eric Burks, Raphaël Szalat(Boston University)
Cited by 2
Related Papers
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615
Systemic immunoglobulin light chain amyloidosis
|Nature Reviews Disease Primers|2018|550